The Types classification within the Canine Oral Chewable Tablets market taxonomy distinguishes four product families: antibiotic tablets, probiotic tablets, dental‑care tablets, and vitamin/mineral supplement tablets. Antibiotic tablets are formulated with broad‑spectrum agents such as amoxicillin or clindamycin, targeting bacterial infections of the oral cavity; they occupy a modest share because prescription constraints limit over‑the‑counter sales. Probiotic tablets contain live cultures (e.g., Lactobacillus spp.) designed to modulate oral microbiota, a segment gaining traction as owners seek non‑antibiotic preventive solutions, now accounting for roughly 15 % of volume. Dental‑care tablets are further divided into subtypes: plaque‑control, tartar‑control, and anti‑inflammatory, each delivering specific actives like zinc‑aspartate or chlorhexidine; this family drives the majority of revenue, reflecting its direct alignment with veterinary treatment protocols. Vitamin/mineral supplement tablets supply essential nutrients such as calcium, vitamin D, and omega‑3 fatty acids to support overall oral health and systemic bone integrity, representing a stable but lower‑margin niche. The relative contribution of each type is quantified by formulation cost, dosage frequency, and reimbursement pathways, collectively shaping the market’s revenue architecture.
